Skip to content

Roles of Gastric Microbiota in Helicobacter pylori-induced Antralization and Gastric Carcinogenesis and the Underlying Mechanisms

Screening of specific serum biomarkers for antral gastritis and correlation between gastric microecology and Helicobacter pylori-induced distal gastric antral gastritis and gastric cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900021943
Enrollment
Unknown
Registered
2019-03-17
Start date
2019-03-30
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

antralization

Interventions

Antral versus non-antral groups:Nil

Sponsors

First Affiliated Hospital of Guangdong Pharmaceutical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
No minimum to 100 Years

Inclusion criteria

Inclusion criteria: (1)People who can tolerate gastroscopy; (2) Gastroscopy was performed for symptoms of indigestion (including upper abdominal pain, upper abdominal distension, early satiety, belching, nausea, vomiting and other upper abdominal discomforts); (3) Voluntarily join the study and sign the relevant informed consent.

Exclusion criteria

Exclusion criteria: 1. Complicated with severe heart, lung, brain, liver and other serious systemic diseases, or mental disorders can not cooperate; 2. History of gastric surgery: including surgery, endoscopic mucosal resection (EMR) and dissection (ESD); 3. Those who are taking aspirin, warfarin and other anticoagulants or have coagulation dysfunction; 4. Gastric juice contains bile, blood and food residues; 5. Those who refuse to be examined; 6. Take Weilang patients in advance; 7. Pregnancy patients; 8. Medication history: Take the following drugs within one month before collecting specimens: (1) Antibiotics (oral, intramuscular and intravenous administration); (2) Microecological agents (probiotics, probiotics and synbiotics, etc.); (3) Various drugs that inhibit gastric acid secretion (proton pump inhibitors and H2 receptor antagonists, etc.); (4) Cytokines, immunosuppressants and cytotoxic agents, etc.; (5) Hormones; (6) Other drugs affecting gastric microflora.

Design outcomes

Primary

MeasureTime frame
TFF2;gastric juice;MUC6;MUC5AC;MUC5B;Gastric Microecology 1;Gastric Microecology 2;High Performance Liquid Chromatography;vitaminC;ascorbic acid;nitrite;Routine blood test;

Countries

China

Contacts

Public ContactHe Xing-Xiang

First Affiliated Hospital of Guangdong Pharmaceutical University

13724887928@qq.com+86 13724887928

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026